Llwytho...
The safety of JAK-1 inhibitors
As efficacy and safety data emerge, differences between JAK inhibitor subclasses are appearing. JAK1 selective drugs, upadacitinib and filgotinib, have broadly come with the same overarching safety recommendations as other immunosuppressive drugs for RA: caution is needed regarding infection risk; m...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Rheumatology (Oxford) |
|---|---|
| Prif Awduron: | , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Oxford University Press
2021
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8098103/ https://ncbi.nlm.nih.gov/pubmed/33950230 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/rheumatology/keaa895 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|